Psychedelic Research Chemicals or RC Chems are new synthetic substances which are structurally similar to the original drug, while being functional analogs. Data on their effects limited due as they’re fairly new and do not have a lot of human consumption history.

Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

This is a commonly used substance with well known effects, but that does not guarantee the substance will be safe. The safety profile has been established based on usage data commonly reported by others.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Description

25I-NBOMe Also known as:

  • 2-(4-Iod-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamin[German][ACD/IUPAC Name]
  • 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine[ACD/IUPAC Name]
  • 2-(4-Iodo-2,5-diméthoxyphényl)-N-(2-méthoxybenzyl)éthanamine[French][ACD/IUPAC Name]
  • 2,5-DIMETHOXY-4-IODO-N-(2-METHOXYBENZYL)PHENETHYLAMINE
  • 25I-NBOMe
  • 547KGL06IP
  • Benzeneethanamine, 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-[ACD/Index Name]
  • 2-(4-iodo-2,5-dimethoxy-phenyl)ethyl-(2-methoxybenzyl)amine
  • 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
  • 2-(4-iodo-2,5-dimethoxy-phenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
  • 2C-I-NBOMe
  • N-(2-methoxybenzyl)-2-(4-iodo-2,5-dimethoxyphenyl)ethanamine
  • NBOMe-2C-I
  • UNII:547KGL06IP
  • UNII-547KGL06IP

A relatively new and popular research chemical with psychedelic properties. Users report an uncomfortable body load with very strong visuals, though with less of a mental aspect than most psychedelics. Commonly mis-sold as LSD, since it is much cheaper to produce. Is considered quite unsafe, and has caused several deaths at ‘regular’ doses.

Summary

The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic 2C-I. It was first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin. It was further researched by a team at Purdue University led by David Nichols.

It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET). It is worth noting that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one’s mouth and allowing it to absorb over a period of 15-25 minutes. Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans.

It had no history of human use before being sold online as a designer drug in 2010. . It has been associated with many deaths and hospitalizations.

Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects.

Chemistry

25I-NBOMe

25I-NBOMe

25I-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as an iodine atom attached to carbon R4.

It differs from 2C-I structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group.

25I-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family.

This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Common Name25I-NBOMe
Systematic name25I-NBOMe
FormulaC_{18}H_{22}INO_{3}
SMILESCOc1ccccc1CNCCc2cc(c(cc2OC)I)OC
Std. InChiInChI=1S/C18H22INO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3
Std. InChiKeyZFUOLNAKPBFDIJ-UHFFFAOYSA-N
Avg. Mass427.2767 Da
Molecular Weight427.2767
Monoisotopic Mass427.064423 Da
Nominal Mass427
ChemSpider ID8427392

Subscribe for the latest updates

Dose Chart

Sublingual
Threshold50-250ug
Light200-500ug
Common500-750ug
Strong700-1000ug+

Duration Chart

25I-NBOMe Duration Data
Onset45-90 minutes
Duration5-10 hours
After-effects6-24 hours

Auditory Effects

Psychological Effects

The cognitive effects of 25I-NBOMe are described by many as notably light in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, strong to overwhelming cognitive alterations become present, which can lead to states of confusion, amnesia, and general sensory overload. The most prominent of these cognitive effects generally include:

Pharmacological Effects

25I-NBOMe has efficacy at the 5-HT2A receptor where it acts as an unusually potent and selective partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor. Contrary to popular belief, it is not a “full agonist”, although questions have been raised about how the effects it produces differ from other 5-HT2a partial agonists, which include the range of traditional psychedelics. The Ki values of the following targets were greater than 500 Ki: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin reuptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine reuptake transporter.

Physical Effects

Sensory Effects

  • Dosage independent intensity - While the reasons for this are not understood, many reports suggest that this substance can produce unexpectedly strong or weak effects even when taken at the seemingly same dose in an unpredictable manner. This may contribute to the relative risk it is poses compared to most other psychedelics.
  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Subjective Effects

Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Visual Effects

Enhancements

Suppressions

Distortions

Geometry

The visual geometry produced by this substance is similar to LSD and can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colorful in scheme, glossy in color, sharp around the edges and equally angular as well as rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages.

25I-NBOMe’s geometry leads reliably leads to Level 8A visual geometry with Level 8B remaining so far unconfirmed. It seems to consistently be able to build up in visual intensity when the user stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.

Hallucinatory states

25I-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very different and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT.

These effects include:

Legal Status

  • Australia: Possession, production and sale is illegal.
  • Austria: Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
  • Canada: 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
  • China: As of October 2015 25I-NBOMe is a controlled substance in China.
  • Denmark: 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.
  • Germany: 25I-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Finland: 25I-NBOMe is controlled under the Medicines Act (395/87) as of March 15, 2013.
  • Hungary: 25I-NBOMe falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.
  • Israel: The drug was banned in 2012.
  • Italy: In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.
  • Latvia: 25I-NBOMe is a Schedule I controlled substance.
  • New Zealand: 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.
  • Norway: 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.
  • Poland: 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. As such its marketing and production is penalised with a fine (administrative sanctions).
  • Romania: In 2011, Romania banned all psychoactive substances, no matter what they really are.
  • Russia: Possession, production and sale is illegal.
  • Slovenia: 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).
  • Sweden: 25I-NBOMe is classed as Schedule I.
  • United Kingdom: 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
  • United States: On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.
  • Sources

    References

    1. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
    2. "Fatalities / Deaths". Erowid. April 26 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
    3. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
    4. Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.
    5. Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.
    6. https://www.ncbi.nlm.nih.gov/pubmed/21174090
    7. http://bitnest.ca/external.php?id=%18%3A3%172%1BE%24K%5BG%21%24%7D%04%04V
    8. Ettrup, A. E. A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging 38 (4): 681–693. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/21174090
    9. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/18468904
    10. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/21174090
    11. "Fatalities / Deaths". Erowid. April 26, 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
    12. http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/
    13. "Kids overdosing on new drug. Laura Geller, WWBT NBC12, Feb 18, 2012 | http://www.nbc12.com/story/16964534/kids-overdosing-on-new-drug
    14. New street drug causing concern among medics. Vanessa Araiza, WBRC, Feb 28, 2012, | http://www.wsfa.com/story/16977573/new-street-drug-causing-concern-among-medics
    15. New drug N-bomb hits the street, terrifying parents, troubling cops | http://www.nydailynews.com/news/national/new-synthetic-hallucinogen-n-bomb-killing-users-cops-article-1.1336327
    16. Breaking Bad: Digital Drug Sales, Analog Drug Deaths. Craig Malisow, Houston Press, March 13, 2013 | http://www.houstonpress.com/2013-03-14/news/motion-research-charles-carlton/
    17. 21-year-old dies after one drop of new synthetic drug at Voodoo Fest. Naomi Martin, NOLA, November 1, 2012 | http://www.nola.com/crime/index.ssf/2012/11/21-year-old_dies_after_one_dro.html#incart_m-rpt-2/
    18. New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man's bizarre death | http://www.adelaidenow.com.au/news/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-e6frea83-1226472672220/
    19. https://erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
    20. https://erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
    21. https://erowid.org/chemicals/nbome/nbome_death.shtml
    22. https://onlinelibrary.wiley.com/doi/full/10.1002/dta.2751
    23. https://www.sciencedirect.com/science/article/abs/pii/S0033318218304882
    24. https://www.sciencedirect.com/science/article/abs/pii/S0378427418317533
    25. https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig
    26. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
    27. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
    28. http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知
    29. "25I-NBOMe: EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine)" (PDF). European Monitoring Centre for Drugs and Drug Addiction. 2014. :10.2810/27828.  978-92-9168-682-7.  1977-7868. Retrieved February 18, 2020.
    30. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
    31. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
    32. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
    33. http://www.health.gov.il/LegislationLibrary/25574413.pdf
    34. Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf
    35. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
    36. http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576
    37. http://drogriporter.hu/node/2211
    38. http://www.dreptonline.ro/legislatie/legea_194_2011_comba
    39. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
    40. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
    41. http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.